scholarly journals A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution

Cureus ◽  
2021 ◽  
Author(s):  
Tomasz Skrzypczak ◽  
Aleksandra Jany ◽  
Ewa Bugajska-Abramek ◽  
Joanna Bogusławska ◽  
Agnieszka Kowal-Lange
Keyword(s):  
Comparative Study ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Tertiary Institution ◽  
Therapeutic Program ◽  
Age Related

scholarly journals Pupillometric evaluation of patients suffering from age related macular degeneration (AMD): a comparative study with electrophysiological and optical methods

2006 ◽  
Vol 5 (S1) ◽  
Author(s):  
Catherine Brozou ◽  
Evangelia Theodoridou ◽  
Vasilios Stergiou ◽  
Dimitrios Tsiptsios ◽  
Irene Kalliolia ◽  
...  
Keyword(s):  
Comparative Study ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Optical Methods ◽  
Age Related

One-year outcomes of the Polish treatment program for the wet form of age-related macular degeneration using intravitreal therapy

2020 ◽  
Vol 30 (3) ◽  
pp. 586-594
Author(s):  
Małgorzata Figurska ◽  
Anna Matysik-Wożniak ◽  
Joanna Adamiec-Mroczek ◽  
Joanna Dolar-Szczasny ◽  
Marta Misiuk-Hojło ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Treatment Program ◽  
Median Number ◽  
Age Related Macular Degeneration ◽  
Therapeutic Program ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
Treatment Naïve ◽  
Best Corrected Visual Acuity

Purpose: To report 12-month outcomes of a Polish National Treatment Program using aflibercept and ranibizumab in eyes with wet, age-related macular degeneration in routine clinical practice. Material and Methods: This was a non-randomized, retrospective, observational multicenter study. Anonymous data contained in the electronic Therapeutic Program Monitoring System were utilized in this study. Results: The study population consisted of 2828 eyes from 2718 patients. The median age was 76.0 [70.0, 81.0] years; 61.7% were female. Best corrected visual acuity increased from 58.86 [50.05, 69.95] letters to 65.1 [50.1, 73.9] letters (p < 0.001). The median change in best corrected visual acuity was 0.0 [−4.0, 12.2] letters: 2.9 [−2.9, 15.1] letters for treatment-naïve eyes and 0.0 [−4.0, 8.8] letters for those continuing treatment (p < 0.001). The median central retinal thickness was significantly reduced from 341.0 [281.0, 422.0] to 275.0 [221.0, 344.0] μm (p < 0.001). The median number of visits was 9.0 [8.0, 9.0]. The median number of injections was 7.0 [6.0, 8.0]: 8.0 [7.0, 8.0] for treatment-naïve eyes and 6.0 [5.0, 7.0] for those continuing treatment (p < 0.001). Conclusion: Eyes treated as part of the Polish therapeutic program gained functional stability and morphological improvement. Treatment-naïve eyes showed the greatest functional benefit.

Sign in / Sign up

Export Citation Format

Share Document